Plant Name: Tetradium glabrifolium
Taxonomic Information:
Plant ID: NPO23772
Plant Latin Name: Tetradium glabrifolium
Taxonomy Genus: Tetradium
Taxonomy Family: Rutaceae
Plant External Links:
NCBI TaxonomyDB:
354522
Plant-of-the-World-Online:
909758-1
Used in Medicines:
Unknown.
Geographical Distribution:
Bangladesh; Myanmar; Philippines; Cambodia; Vietnam; Laos; Thailand
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; GPR35; | |
| RECQL; TDP1; ADK; HPGD; AKR1B1; APEX1; POLB; | |
| ACHE; | |
| TEK; INSR; MET; NUAK1; EGFR; SRC; KDR; IGF1R; CSNK2A1; | |
| CA2; CA1; CA12; CA9; CA14; CA7; | |
| KDM4E; | |
| PTGS2; | |
| STAT1; | |
| FUT7; | |
| KMT2A; | |
| SLC22A6; | |
| SMAD3; LMNA; RAB9A; NPC1; THPO; HSPA1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | P42224 | CHEMBL6101 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.590E-13 | 7.292E-09 | CA1, CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.834E-10 | 6.192E-07 | CA1, CA12, CA14, CA2, CA7, CA9 |
| MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 4.090E-09 | 3.071E-06 | EGFR, IGF1R, INSR, KDR, MET, TEK |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.363E-08 | 7.809E-06 | CA1, CA12, CA2, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 5.448E-08 | 2.524E-05 | EGFR, IGF1R, INSR, KDR, SRC |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.391E-07 | 5.508E-05 | ADORA1, CA2, CA9, EGFR, HPGD, SLC22A6, TEK |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 3.325E-07 | 1.065E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 6.265E-07 | 1.819E-04 | AKR1B1, EGFR, HPGD, PTGS2, STAT1 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 7.957E-07 | 2.113E-04 | ADORA1, ADORA2A, ADORA3 |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 7.957E-07 | 2.113E-04 | EGFR, INSR, KDR |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 8.930E-07 | 2.288E-04 | EGFR, INSR, MET, SRC, TEK, THPO |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.135E-06 | 2.746E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 1.299E-06 | 3.041E-04 | ADORA1, CYP1A1, LMNA, PTGS2, SMAD3, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 1.844E-06 | 4.016E-04 | EGFR, INSR, PTGS2, SMAD3 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 1.984E-06 | 4.235E-04 | ADORA1, ADORA2A, ADORA3, CYP1B1, HSPA1A, KMT2A, LMNA, PTGS2, SMAD3, STAT1 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 2.693E-06 | 5.189E-04 | ADORA2A, CA2, CA7 |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 3.917E-06 | 7.048E-04 | AKR1B1, CA12, CA2, CA7, EGFR, GPR35, INSR, MET, NPC1, SMAD3, STAT1 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 4.616E-06 | 8.171E-04 | APEX1, POLB |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 4.834E-06 | 8.374E-04 | ACHE, ADORA2A, CSNK2A1, EGFR, HPGD, IGF1R, KDR, KMT2A, MET, PTGS2, RAB9A, SLC22A6, SMAD3, STAT1 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 5.508E-06 | 9.225E-04 | ADORA1, ADORA2A, CA2, CA7, KDR, SRC |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 8.057E-06 | 1.244E-03 | APEX1, CYP1A1, CYP1A2, KDM4E |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.256E-06 | 1.257E-03 | CYP1A1, CYP1A2, CYP1B1, PTGS2, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 8.904E-06 | 1.328E-03 | EGFR, IGF1R, INSR, KDR, TEK |
| BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 1.237E-05 | 1.716E-03 | CA2, PTGS2, SRC |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.237E-05 | 1.716E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.383E-05 | 1.826E-03 | CA2, CA7 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.383E-05 | 1.826E-03 | ADORA1, ADORA2A |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 1.538E-05 | 1.994E-03 | ACHE, ADK, AKR1B1, CYP1A1, CYP1A2, CYP1B1, EGFR, HSPA1A |
| BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 1.564E-05 | 2.015E-03 | ADORA2A, APEX1, PTGS2, STAT1, TEK |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.642E-05 | 2.069E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.642E-05 | 2.069E-03 | CYP1A1, CYP1A2, CYP1B1 |
| CC | GO:0016020; membrane | GO:0005901; caveola | 1.688E-05 | 2.112E-03 | INSR, PTGS2, SLC22A6, SRC |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.762E-05 | 3.165E-03 | CYP1A1, CYP1A2 |
| BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 3.097E-05 | 3.389E-03 | CA2, CA9, EGFR, MET, SMAD3, SRC |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 3.441E-05 | 3.691E-03 | ACHE, EGFR, IGF1R, INSR |
| BP | GO:0032501; multicellular organismal process | GO:0035295; tube development | 3.738E-05 | 3.970E-03 | AKR1B1, CYP1A1, EGFR, SMAD3, STAT1 |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 3.922E-05 | 4.126E-03 | ACHE, ADORA1, APEX1, CSNK2A1, EGFR, IGF1R, INSR, KDR, SMAD3, SRC |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 4.164E-05 | 4.256E-03 | ACHE, ADORA3, CYP1A1, EGFR, SMAD3 |
| MF | Unclassified; | GO:0032403; protein complex binding | 4.251E-05 | 4.326E-03 | ACHE, ADORA1, APEX1, EGFR, IGF1R, INSR, KDR, SMAD3, SRC |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 4.868E-05 | 4.796E-03 | ADK, CSNK2A1, EGFR, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, RECQL, SRC, TEK |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 6.537E-05 | 6.135E-03 | ACHE, AKR1B1, APEX1, EGFR, HSPA1A, NPC1, SRC, STAT1 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 6.566E-05 | 6.136E-03 | EGFR, KDR, SRC, TEK, THPO |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 6.885E-05 | 6.407E-03 | CA1, CA2 |
| MF | GO:0005488; binding | GO:0046914; transition metal ion binding | 7.616E-05 | 6.939E-03 | CA1, CA12, CA2, CA7, CA9, CYP1A1, CYP1A2, CYP1B1, KMT2A, SMAD3 |
| MF | GO:0005488; binding | GO:0031072; heat shock protein binding | 7.871E-05 | 7.112E-03 | ADORA1, CSNK2A1, HSPA1A, KDR |
| MF | Unclassified; | GO:0004872; receptor activity | 8.035E-05 | 7.200E-03 | ADORA1, ADORA2A, ADORA3, EGFR, GPR35, HPGD, IGF1R, INSR, KDR, MET, NPC1, TEK |
| MF | GO:0003824; catalytic activity | GO:0032451; demethylase activity | 8.272E-05 | 7.352E-03 | CYP1A1, CYP1A2, KDM4E |
| BP | GO:0009987; cellular process | GO:0007169; transmembrane receptor protein tyrosine kinase signaling pathway | 9.071E-05 | 7.932E-03 | EGFR, IGF1R, INSR, KDR, MET, SRC, TEK |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 9.626E-05 | 8.156E-03 | EGFR, POLB |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.121E-04 | 9.071E-03 | ADORA1, ADORA2A, SMAD3, TEK |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 7.186E-13 | 9.845E-11 | CA12, CA1, CA2, CA7, CA9, CA14 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.727E-10 | 1.183E-08 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.166E-08 | 5.323E-07 | ADORA2A, SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 6.309E-08 | 2.161E-06 | INSR, CYP1A1, CYP1B1, PTGS2, IGF1R |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 1.032E-06 | 2.828E-05 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 7.460E-06 | 1.703E-04 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 7.348E-05 | 9.152E-04 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 6.428E-05 | 8.807E-04 | SRC, KDR, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 6.279E-05 | 8.807E-04 | SRC, KDR, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.609E-05 | 5.106E-04 | CYP1A2, CYP1A1, CYP1B1, PTGS2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 6.388E-05 | 8.807E-04 | INSR, TEK, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.688E-04 | 1.683E-03 | SMAD3, STAT1, PTGS2, MET, EGFR, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 8.060E-05 | 9.202E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 1.720E-04 | 1.683E-03 | SMAD3, INSR, EGFR, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.874E-04 | 1.711E-03 | CSNK2A1, STAT1, RAB9A, HSPA1A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 2.209E-04 | 1.892E-03 | INSR, ADORA1, PTGS2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 2.847E-04 | 2.167E-03 | SRC, KDR, PTGS2 |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 3.282E-04 | 2.366E-03 | INSR, HSPA1A, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 3.594E-04 | 2.462E-03 | SMAD3, STAT1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 4.456E-04 | 2.775E-03 | MET, EGFR, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.925E-04 | 2.560E-03 | SRC, MET, EGFR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.452E-04 | 1.976E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 5.438E-04 | 3.104E-03 | HPGD, KMT2A, MET, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.174E-03 | 6.434E-03 | SRC, EGFR, HSPA1A |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.835E-04 | 2.880E-03 | CYP1A2, CYP1A1, CYP1B1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; INSR; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MET; IGF1R; KDR; CSNK2A1; ACHE; ADORA3; TEK; EGFR; PTGS2; SRC; CA1; CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; INSR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; AKR1B1; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; EGFR; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; PTGS2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; EGFR; PTGS2; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; CA9; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; EGFR; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; INSR; AKR1B1; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; ADORA1; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | IGF1R; ACHE; ADORA2A; INSR; ADK; PTGS2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; EGFR; PTGS2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; TEK; SRC; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Prostate cancer | C61 | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| C00-D49: Neoplasms | AML | NA | KDR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Skin infections | L00-L99 | STAT1; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; IGF1R; KDR; TEK; EGFR; SRC; CA9; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Breast cancer | C50 | IGF1R; KDR; INSR; EGFR; CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; PTGS2; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; AKR1B1; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA1; ADORA2A; ADORA3; AKR1B1; CA1; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
